Safety and Efficacy Study of TRC150094 to Improve the CV Risk in Subjects With Diabetes, Dyslipidemia and Hypertension

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 1250 participants.

Also called NCT03254446

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,250 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT03254446
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Brazil, India, Philippines (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT03254446. Randomized; quadruple masking; primary purpose treatment. Start 2018-03-12 (actual); primary completion 2022-04 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Efficacy Study of TRC150094 to Improve the CV Risk in Subjects With Diabetes, Dyslipidemia and Hypertension
Condition
Diabetes
Condition
Dyslipidemias
Condition
Hypertension
Intervention (Drug)
TRC150094
Intervention (Drug)
Placebo
Lead sponsor
Torrent Pharmaceuticals Limited (class: industry)
Collaborator
IQVIA Pty Ltd (class: industry)

Record details

Record id
cardio:ct-nct03254446
Content hash
6341b1964456ad75ef73008ab76013f859c776d9accf84d3bc96a581cde685f0